Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, Estebán Martínez, José L Blanco et al.|The Lancet HIV|2025Cited by 22
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)Sergio Serrano‐Villar, Santiago Moreno, Laura Martín‐Pedraza et al.|Clinical Infectious Diseases|2025Cited by 7
Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysisGundolf Schuettfort, Annette E. Haberl, Carmen Hidalgo‐Tenorio et al.|HIV Medicine|2025Cited by 1